Key Facts about mRNA
Messenger RNA (mRNA) is a single-stranded ribonucleic acid molecule that carries genetic information from DNA to the ribosome, where it directs the synthesis of a specific protein. Unlike traditional biologics, therapeutic mRNA is not produced inside living host cells, but generated cell-free in an enzymatic in vitro transcription (IVT) reaction — making mRNA manufacturing fundamentally different from classical mammalian or microbial bioprocesses.
mRNA molecules are inherently unstable, highly susceptible to ribonucleases (RNases), and sensitive to temperature, pH, and ionic conditions. Their integrity, capping efficiency, poly(A) tail length, and the level of double-stranded RNA (dsRNA) by-products directly determine translational efficiency, immunogenicity, and therapeutic safety — making tightly controlled bioreactor conditions, low-shear environments, and thermal homogeneity essential for high-quality mRNA production.
As a versatile platform technology, the same manufacturing process can be rapidly adapted to new targets by exchanging the DNA template — enabling vaccines (e.g. COVID-19, influenza, RSV), cancer immunotherapies, protein replacement therapies, and gene editing tools such as CRISPR-Cas9 delivery. These properties shape the requirements for any bioreactor used in mRNA production: precise temperature control, gentle mixing, minimal hold-up volume, and operation under fed-batch or continuous IVT regimes.
The mRNA Process: From Lab to Therapy
The process of developing mRNA for therapeutic applications merges molecular biology, genetic engineering, and bioprocess technology — requiring a series of precisely controlled steps from initial sequence design to delivery into patient cells.
-
mRNA sequence design and optimization
The journey begins with rational design of the mRNA sequence: codon optimization, GC content, 5′ and 3′ UTRs, and poly(A) tail length are tuned to enhance stability, translation efficiency, and expression fidelity. Modified nucleosides such as N1-methylpseudouridine dampen innate immune activation while preserving protein output, and computational tools refine secondary structure to minimize uridine content and avoid sequences prone to dsRNA formation.
Learn more -
In Vitro Transcription (IVT)
A linearized DNA plasmid carrying a T7, T3, or SP6 promoter is incubated with RNA polymerase, NTPs, a cap analogue or co-transcriptional capping system, magnesium, and supportive enzymes (RNase inhibitors, pyrophosphatase). Yield depends strongly on NTP and Mg2+ stoichiometry, temperature, pH, and reaction time. Fed-batch IVT in controlled bioreactors has pushed mRNA titers above 10 g/L while reducing dsRNA byproducts compared to conventional batch reactions — a key step toward continuous, GMP-ready mRNA biomanufacturing
Learn more -
Purification and quality assurance
The crude IVT mixture is purified through DNase digestion, tangential flow filtration, oligo-dT affinity capture, ion-exchange chromatography, and ion-pair reversed-phase HPLC for dsRNA removal. Critical quality attributes — mRNA integrity, capping efficiency, poly(A) tail length, dsRNA content — are characterized by IP-RP HPLC, anion-exchange HPLC, capillary gel electrophoresis, and orthogonal bioassays. Robust QC is essential because even trace dsRNA can trigger innate immune sensors and reduce protein expression up to 1000-fold.
Learn more -
mRNA encapsulation and delivery
Purified mRNA is formulated into lipid nanoparticles (LNPs) comprising four lipid classes: an ionizable cationic lipid, helper phospholipid, cholesterol, and PEG-lipid. Their molar ratios determine encapsulation efficiency, particle size, polydispersity, biodistribution, and tissue tropism. LNPs are most commonly produced by rapid microfluidic or T-junction mixing of an ethanolic lipid phase with an aqueous mRNA phase, followed by buffer exchange and sterile filtration — with flow ratio, total flow rate, and lipid composition tightly controlled to deliver consistent particle quality at clinical and commercial scale.
Learn more -
Scaling up production with bioreactors
Scaling up mRNA production from research to clinical and commercial supply requires bioreactors that provide tight control over temperature, pH, mixing, and feed addition for cell-free IVT — and for upstream plasmid DNA fermentation. Single-use and small-scale bioreactors enable parallel screening of IVT conditions, NTP feeding strategies, and Mg2+ profiles, while linear, predictive scale-up from millilitre development volumes to litre-scale GMP production is a hallmark of modern Biopharma 4.0 mRNA platforms supporting fed-batch and continuous IVT modes.
Learn more -
Clinical application and monitoring
The final mRNA therapeutic is administered to patients through routes appropriate to the target disease and tissue. Patients are closely monitored for therapeutic outcomes and adverse reactions — with efficacy measured by target protein expression levels and clinical improvement.
The Role of Bioreactors in mRNA Production
The field of mRNA therapeutics is rapidly evolving, with mRNA technology offering promising new avenues for treating and preventing diseases. The production of mRNA, from design to large-scale manufacturing, relies on sophisticated equipment that provides the necessary precision and scalability.
Applikon Bioreactor Types for mRNA
All Applikon bioreactor formats can be configured for mRNA-related workflows — from upstream plasmid DNA fermentation in E. coli to fed-batch IVT and downstream conditioning steps. The portfolio covers small-scale process development up to GMP production of mRNA therapeutics.
| Type | Scale | Key Use Cases | mRNA-Specific Features |
|---|---|---|---|
| Applikon MiniBio glass small-scale bioreactor |
0.25–1 L | Process development for fed-batch IVT, NTP/Mg2+ screening, plasmid DNA fermentation, scale-down models | Low working volume reduces costly NTP and enzyme consumption; parallel runs for DoE; scalable mRNA process development |
| Applikon glass autoclavable bioreactors for mRNA workflows |
2–20 L | Plasmid DNA fermentation, optimization of fed-batch IVT, scale-up/scale-down studies for mRNA bioprocess development | Flexible vessel configuration, multi-gas sparging, multiple sensor ports for PAT (HPLC sampling, FTIR/Raman), high reusability |
| AppliFlex ST single-use bioreactor for mRNA |
0.5–15 L | Single-use plasmid DNA fermentation, GMP-ready fed-batch IVT, clinical-scale mRNA production, fast tech transfer | Disposable vessels for closed processing, fast turnaround, reduced cross-contamination risk — critical for multi-product mRNA facilities |
| Stainless-steel bioreactors for large-scale mRNA manufacturing |
20–5000 L | Commercial-scale plasmid DNA fermentation, repeated GMP production runs supporting industrial mRNA vaccine and therapeutic supply | CIP/SIP capability, robust agitation control, validated for cGMP manufacturing, scalable to global mRNA supply demands |
Applications of mRNA Technology
Messenger RNA technology has rapidly advanced to the forefront of biomedicine — offering novel therapeutic applications across a wide range of diseases by exploiting the fundamental biological process of translating mRNA into proteins within cells.
Perhaps the most well-known application of mRNA technology has been in the development of vaccines — particularly highlighted by its pivotal role in addressing the COVID-19 pandemic. mRNA vaccines operate by encoding the spike protein found on the surface of the SARS-CoV-2 virus. When delivered into human cells, the mRNA directs the production of the spike protein, triggering an immune response without causing disease. Beyond COVID-19, mRNA vaccine technology is being explored for a range of infectious diseases — including influenza, Zika virus, and rabies — due to its rapid development timeline and high efficacy.
mRNA technology is being harnessed to develop personalized cancer vaccines and immunotherapies. By sequencing the genome of a patient’s tumor, scientists can identify unique mutations and design mRNA that encodes neoantigens specific to the patient’s cancer cells. When delivered to the patient, the mRNA vaccine induces an immune response specifically targeted at the tumor — offering a highly personalized treatment strategy. Additionally, mRNA is being used to engineer T-cells in the laboratory, creating chimeric antigen receptor (CAR) T-cell therapies that target and kill cancer cells.
mRNA technology offers a promising therapeutic approach for genetic disorders caused by a specific protein deficiency, enabling the in vivo production of the missing or defective protein. Conditions such as cystic fibrosis, hemophilia, and certain metabolic disorders could potentially be treated by administering mRNA that encodes the functional version of the protein. This approach aims to provide a temporary but repeatable means of protein replacement — offering advantages over traditional protein therapy in terms of dosing and delivery.
In the realm of regenerative medicine, mRNA technology is being explored to promote tissue repair and regeneration. Synthetic mRNA can be designed to encode growth factors, transcription factors, or other proteins that stimulate the regeneration of damaged tissues. For example, mRNA encoding VEGF (vascular endothelial growth factor) has been investigated for its potential to promote angiogenesis and heal wounds or restore blood flow to ischemic tissues.
mRNA is critical in delivering the components required for gene editing technologies such as CRISPR-Cas9. Instead of directly delivering the Cas9 protein and guide RNA, cells can be transfected with mRNA encoding the Cas9 nuclease alongside a guide RNA. This enables the cell’s own machinery to produce the Cas9 protein and perform targeted gene editing — amplifying the delivery of gene-editing tools, reducing off-target effects, and paving the way for treating genetic disorders by correcting mutations at the DNA level.
